A novel percutaneous device to aid in treatment of tricuspid endocarditis

Nitish Mittal BS, Rohan Mittal, Joseph Greene BS, Zhaunn Sly MD, Ankush Lahoti MD, Mohammad M Ansari MD


The AngioVac System is used for the removal of thrombus from cardiovascular structures. High risk surgical patients who present with severe valvular disease secondary to endocarditis can be treated with the AngioVac system, hence reducing the risks in these patients. We describe a 56-year-old African American man who presented to the hospital with an infected pacemaker lead. During the lead extraction procedure, residual vegetations of 3.0 × 1.5 cm on the atrial aspect of the tricuspid valve and 1.5 × 1.2 cm on the ventricular aspect were discovered. The AngioVac system was used to decrease the vegetation burden to decrease septic emboli risk and to allow better penetration of antibiotics. Trans-esophageal echocardiography demonstrated a significant reduction (> 80%) in the size of the vegetations. This case illustrates the use of innovative medical technology, the AngioVac system, to remove large vegetations with bacteremia on the tricuspid valve.

Keywords: AngioVac, tricuspid endocarditis, vegetations, trans-esophageal echocardiography

Article citation: Mittal N, Mittal R, Greene J, Sly Z, Lahoti A, Ansari MM. A novel percutaneous device to aid in treatment of tricuspid endocarditis. The Southwest Respiratory and Critical Care Chronicles 2022;10(43):33–36
From: School of Medicine (NM, JG); Department of Internal Medicine (ZS, AL, MMA), Texas Tech University Health Sciences Center, Lubbock, Texas; Texas Tech University (RM), Lubbock, Texas
Submitted: 1/22/2022
Accepted: 1/26/2022
Conflicts of interest: none
This work is licensed under a Creative Commons
Attribution-ShareAlike 4.0 International License.